Table 1.
a. Patient Characteristics. b. Imaging Findings and Clinical Outcomes.
| A | ||||
|---|---|---|---|---|
| All Patients | Hepatic Steatosis | No Hepatic Steatosis | ||
| N = 80 (100%) | N = 59 (73.7%) | N = 21 (26.2%) | P-Value | |
| Age at Transplant (years) | ||||
| Median (IQR) | 49 (34.5–57.5) | 52 (39–58) | 38 (29–54) | 0.052 |
| Sex | ||||
| Female | 31 (38.8%) | 23 (39%) | 8 (38.1%) | 0.94 |
| Pre-transplant Weight (kg) | ||||
| Median (IQR) | 80.15 (70.75–92.5) | 78.6 (71.3–92.6) | 81.8 (68–91) | 0.82 |
| Height (cm) | ||||
| Median (IQR) | 172.8 (164.5–179.05) | 172 (166–179) | 174 (163–179.1) | 0.97 |
| Race | ||||
| White | 64 (80%) | 47 (79.7%) | 17 (81%) | >0.99 |
| Black | 14 (17.5%) | 10 (16.9%) | 4 (19%) | |
| American Indian | 1 (1.3%) | 1 (1.7%) | 0 (0%) | |
| Asian | 1 (1.3%) | 1 (1.7%) | 0 (0%) | |
| Disease | ||||
| Lymphomas | 54 (67.5%) | 41 (69.5%) | 13 (61.9%) | 0.39 |
| MDS/MPN/Other | 20 (25%) | 15 (25.4%) | 5 (23.8%) | |
| Acute Leukemias | 6 (7.5%) | 3 (5.1%) | 3 (14.3%) | |
| Conditioning Class | ||||
| Non-myeloablative | 49 (61.3%) | 39 (66.1%) | 10 (47.6%) | 0.19 |
| Myeloablative | 31 (38.8%) | 20 (33.9%) | 11 (52.4%) | |
| Cell Type | ||||
| Peripheral Blood Progenitor Cells | 71 (88.8%) | 53 (89.8%) | 18 (85.7%) | 0.66 |
| Cord Blood | 7 (8.8%) | 5 (8.5%) | 2 (9.5%) | |
| Bone Marrow | 2 (2.5%) | 1 (1.7% | 1 (4.8%) | |
| Donor Type | ||||
| Unrelated | 44 (55%) | 29 (49.2%) | 15 (71.4%) | 0.08 |
| Related | 36 (45%) | 30 (50.8%) | 6 (28.6%) | |
| HLA Match | ||||
| Fully Matched | 65 (81.3%) | 47 (79.7%) | 18 (85.7%) | 0.75 |
| Unmatched | 15 (18.8%) | 12 (20.3%) | 3 (14.3%) | |
| Post-transplant Cyclophosphamide | 16 (20%) | 9 (15.3%) | 7 (33.3%) | 0.11 |
| Anti-thymocyte Globulin | 9 (11.3%) | 6 (10.2%) | 3 (14.3%) | 0.69 |
| KPS | ||||
| < = 80 | 43 (53.8%) | 32 (54.2%) | 11 (52.4%) | 0.88 |
| >80 | 37 (46.3%) | 27 (45.8%) | 10 (47.6%) | |
| HCT-CI | ||||
| < = 3 | 52 (65%) | 37 (62.7%) | 15 (71.4%) | 0.47 |
| >3 | 28 (35%) | 22 (37.3%) | 6 (28.6%) | |
| Diabetes Mellitus Type II | 15 (18.8%) | 13 (22%) | 2 (9.5%) | 0.21 |
| Hyperlipidemia/dyslipidemia | 14 (17.5%) | 12 (20.3%) | 2 (9.5%) | 0.26 |
| Coronary artery disease | 4 (5%) | 3 (5.1%) | 1 (4.8%) | 0.95 |
| Alcohol Abuse | 1 (1.3%) | 1 (1.7%) | 0 (0%) | >0.99 |
| AST | ||||
| Median (IQR) | 25.5 (19.5–35) | 26 (20.5–37) | 21.5 (16–31.5) | 0.19 |
| ALT | ||||
| Median (IQR) | 25.5 (16.5–48.5) | 26 (16–58) | 23.5 (17.5–31.5) | 0.47 |
| Alkaline Phosphatase | ||||
| Median (IQR) | 68.5 (54.5–85) | 70 (58.5–90) | 58 (44.5–71) | 0.10 |
| Bilirubin Total | ||||
| Median (IQR) | 0.65 (0.5–0.8) | 0.6 (0.5–0.9) | 0.7 (0.5–0.8) | 0.78 |
| Albumin | ||||
| Median (IQR) | 3.3 (3.1–3.8) | 3.35 (3.15–3.7) | 3.25 (3–3.85) | 0.59 |
| Hemoglobin A1C | ||||
| Median (IQR) | 5.35 (5.15–6.5) | 5.3 (5–7.6) | 5.4 * | N/A |
| B | ||||
| Imaging Findings: | ||||
| Subcutaneous fat cross-sectional area at L3 (cm2) | ||||
| Median (IQR) | 210.17 (148.13–318.82) | 207.41 (148.19–318.26) | 212.93 (128.13–319.13) | 0.91 |
| Visceral fat cross-sectional area at L3 (cm2) | ||||
| Median (IQR) | 118.1 (77.17–207.65) | 118.55 (77.91–217.82) | 117.64 (74.52–171.29) | 0.50 |
| Skeletal muscle cross-sectional area at L3 level (cm2) | ||||
| Median (IQR) | 162.9 (128.85–186.32) | 158.52 (128.15–187.57) | 168.3 (129.56–182.98) | 0.89 |
| Clinical Outcomes: | ||||
| Acute Graft vs Host Disease, grade II-IV | 53 (66.3%) | 39 (66.1%) | 14 (66.7%) | >0.99 |
| Chronic Graft vs Host Disease | 35 (43.8%) | 29 (49.2%) | 6 (28.6%) | 0.13 |
| Days to discharge from Transplant | ||||
| Median (IQR) | 85 (63.5–98) | 85 (65–99) | 83 (57–92) | 0.99 |
*Only one patient in No Hepatic Steatosis group had HbA1C data.
MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; HLA: human leukocyte antigens; KPS: Karnofsky Performance Score; HCT-CI: Hematopoietic Cell Transplantation-Comorbidity Index; AST: Aspartate transaminase; ALT: Alanine transaminase